Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Stock Price Up 0.3% – Here’s Why

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR)’s share price rose 0.3% during trading on Monday . The stock traded as high as $25.80 and last traded at $25.80. 980 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 2,122 shares. The stock had previously closed at $25.72.

Amplify Weight Loss Drug & Treatment ETF Price Performance

The firm has a fifty day simple moving average of $24.97 and a two-hundred day simple moving average of $25.16. The firm has a market capitalization of $5.16 million, a P/E ratio of 24.31 and a beta of 0.37.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC boosted its position in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 24,891 shares of the company’s stock after acquiring an additional 1,215 shares during the period. Jane Street Group LLC owned 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 as of its most recent SEC filing.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.